Growing a Compounding Practice: Successful Marketing to Underserved Populations.

In this article, we provide an example of an effective novel therapy plan (the Stanley Protocol) that compounders can offer or use as a template for other services to grow their pharmacy practice, expand their role in patient care, and provide essential assistance for prescribers. We also share our successful consultative strategy for marketing that plan, which consists of several elements: identifying a treatment vacancy in underserved populations, changing the paradigm of compounding services, developing strategies that reach target populations, and dedicating the time and effort necessary to implement those strategies. Since we introduced the Stanley Protocol to prescribers and patients in 2020, our compounding practice has grown substantially in a number of aspects, which we describe in detail in this article.

The Stanley Prostate-cancer Treatment Protocol for Erectile Dysfunction After Prostatectomy and/or Radiotherapy: A Case Report.

Even when a diagnosis of prostate cancer is anticipated, many patients are unprepared for the persistence and severity of sequelae such as erectile dysfunction, which frequently results from lifesaving treatment for that disease. Erectile dysfunction in particular can exert a powerful impact on quality of life as the patient's self-esteem diminishes, intimacy erodes, and a sustained level of stress and anxiety that impairs work performance and personal relationships becomes a part of his everyday experience. The Stanley Prostate-cancer Protocol for treating erectile dysfunction after prostatectomy and/or radiotherapy was developed to better assist the underserved patient population faced with that challenge.

Reversing Erectile Dysfunction and Urinary Incontinence After Prostatectomy or Radiotherapy: The Stanley Prostate-Cancer Treatment Protocol.

Although prostatectomy and radiotherapy yield excellent- long term survival rates for men with prostate cancer, adverse effects (erectile dysfunction and/or urinary incontinence with subsequent undesired lifestyle modifications, anxiety about the loss of intimacy, negative self-perception, and the effects of such stressors on work performance and family relationships) frequently afflict patients who have undergone these procedures. Surgeons who specialize in the treatment of prostate cancer are dedicated to ensuring the optimal clinical result but often do not provide information about the likelihood of experiencing those sequelae or the additional support and aftercare necessary to ensure posttreatment sexual and urologic function to their patients' satisfaction. In response to the needs of these underserved patients, the authors designed the Stanley Prostate-cancer Treatment Protocol for erectile dysfunction and urinary incontinence.

U.S. Food and Drug Administration Inspections: Guide to a Successful Outcome for 503A Sterile Compounding Pharmacies.

The reasons for which pharmaceutical compounding is the focus of intense state and federal scrutiny are now well known. Compounders are faced with an ever-increasing need to prove, by objective standards, the safety, purity, and potency of the formulations they dispense. They must also demonstrate their compliance with regulations often based on current good compounding practices designed for the pharmaceutical industry.

Compounding for pediatric patients: case reports and formulations.

When no commercially available agent is appropriate for a pediatric patient, a compounded formulation often assures successful treatment. In the following case reports of five children, a pharmaceutical compound is an essential component of long-term therapy for a disorder best managed with customized medications and supplements.